This TIM-3/galectin-9 pathway seems to be involved in the immune escape of AML cells [43], and the dual targeting of PD-1/PD-L1 and TIM-3/galectin-9 may therefore be a possible therapeutic strategy in AML [44]. Here, HAVCR2 is linked to acute myeloid leukemia.